OCEAN Trial: Ablate Afib. Assess. Anticoagulate? 🌊

🌊 OCEAN Trial offers fresh insight into antithrombotic therapy after successful AF ablation. In 1284 patients followed for 3 years, event rates were remarkably low 🌟. Rivaroxaban did not show superiority over aspirin for preventing stroke, systemic embolism, or covert embolic events, while bleeding risk was higher with anticoagulation.   🧠 96% had no new infarcts on MRI at follow-up.   Published in NEJM (2025) — a valuable contribution to nuanced AF post-ablation care.